Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. / Polman, Chris H; Bertolotto, Antonio; Deisenhammer, Florian; Giovannoni, Gavin; Hartung, Hans-Peter; Hemmer, Bernhard; Killestein, Joep; McFarland, Henry F; Oger, Joel; Pachner, Andrew R; Petkau, John; Reder, Anthony T; Reingold, Stephen C; Schellekens, Huub; Sørensen, Per Soelberg.

I: Lancet Neurology, Bind 9, Nr. 7, 01.07.2010, s. 740-50.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Polman, CH, Bertolotto, A, Deisenhammer, F, Giovannoni, G, Hartung, H-P, Hemmer, B, Killestein, J, McFarland, HF, Oger, J, Pachner, AR, Petkau, J, Reder, AT, Reingold, SC, Schellekens, H & Sørensen, PS 2010, 'Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis', Lancet Neurology, bind 9, nr. 7, s. 740-50. https://doi.org/10.1016/S1474-4422(10)70103-4

APA

Polman, C. H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H-P., Hemmer, B., Killestein, J., McFarland, H. F., Oger, J., Pachner, A. R., Petkau, J., Reder, A. T., Reingold, S. C., Schellekens, H., & Sørensen, P. S. (2010). Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology, 9(7), 740-50. https://doi.org/10.1016/S1474-4422(10)70103-4

Vancouver

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung H-P, Hemmer B o.a. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology. 2010 jul. 1;9(7):740-50. https://doi.org/10.1016/S1474-4422(10)70103-4

Author

Polman, Chris H ; Bertolotto, Antonio ; Deisenhammer, Florian ; Giovannoni, Gavin ; Hartung, Hans-Peter ; Hemmer, Bernhard ; Killestein, Joep ; McFarland, Henry F ; Oger, Joel ; Pachner, Andrew R ; Petkau, John ; Reder, Anthony T ; Reingold, Stephen C ; Schellekens, Huub ; Sørensen, Per Soelberg. / Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. I: Lancet Neurology. 2010 ; Bind 9, Nr. 7. s. 740-50.

Bibtex

@article{fae5e479c5bd479fbf21374ff6d3e665,

title = "Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis",

abstract = "The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy. In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. The panel believed that information about NAbs and other markers of biological activity of interferons (ie, myxovirus resistance protein A [MxA]) can be integrated with clinical and imaging indicators to guide individual treatment decisions. In cases of sustained high-titre NAb positivity and/or lack of MxA bioactivity, a switch to a non-interferon-beta therapy should be considered. In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity.",

author = "Polman, {Chris H} and Antonio Bertolotto and Florian Deisenhammer and Gavin Giovannoni and Hans-Peter Hartung and Bernhard Hemmer and Joep Killestein and McFarland, {Henry F} and Joel Oger and Pachner, {Andrew R} and John Petkau and Reder, {Anthony T} and Reingold, {Stephen C} and Huub Schellekens and S{\o}rensen, {Per Soelberg}",

year = "2010",

month = jul,

day = "1",

doi = "http://dx.doi.org/10.1016/S1474-4422(10)70103-4",

language = "English",

volume = "9",

pages = "740--50",

journal = "The Lancet Neurology",

issn = "1474-4422",

publisher = "TheLancet Publishing Group",

number = "7",

}

RIS

TY - JOUR

T1 - Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

AU - Polman, Chris H

AU - Bertolotto, Antonio

AU - Deisenhammer, Florian

AU - Giovannoni, Gavin

AU - Hartung, Hans-Peter

AU - Hemmer, Bernhard

AU - Killestein, Joep

AU - McFarland, Henry F

AU - Oger, Joel

AU - Pachner, Andrew R

AU - Petkau, John

AU - Reder, Anthony T

AU - Reingold, Stephen C

AU - Schellekens, Huub

AU - Sørensen, Per Soelberg

PY - 2010/7/1

Y1 - 2010/7/1

N2 - The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy. In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. The panel believed that information about NAbs and other markers of biological activity of interferons (ie, myxovirus resistance protein A [MxA]) can be integrated with clinical and imaging indicators to guide individual treatment decisions. In cases of sustained high-titre NAb positivity and/or lack of MxA bioactivity, a switch to a non-interferon-beta therapy should be considered. In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity.

AB - The identification of factors that can affect the efficacy of immunomodulatory drugs in relapsing-remitting multiple sclerosis (MS) is important. For the available interferon-beta products, neutralising antibodies (NAb) have been shown to affect treatment efficacy. In June, 2009, a panel of experts in MS and NAbs to interferon-beta therapy convened in Amsterdam, Netherlands, under the auspices of the Neutralizing Antibodies on Interferon beta in Multiple Sclerosis consortium, a European-based project of the 6th Framework Programme of the European Commission, to review and discuss data on NAbs and their practical consequences for the treatment of patients with MS on interferon beta. The panel believed that information about NAbs and other markers of biological activity of interferons (ie, myxovirus resistance protein A [MxA]) can be integrated with clinical and imaging indicators to guide individual treatment decisions. In cases of sustained high-titre NAb positivity and/or lack of MxA bioactivity, a switch to a non-interferon-beta therapy should be considered. In patients who are doing poorly clinically, therapy should be switched irrespective of NAb or MxA bioactivity.

U2 - http://dx.doi.org/10.1016/S1474-4422(10)70103-4

DO - http://dx.doi.org/10.1016/S1474-4422(10)70103-4

M3 - Journal article

VL - 9

SP - 740

EP - 750

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 7

ER -

ID: 34093155